Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 14,740 shares, a decrease of 49.8% from the June 30th total of 29,381 shares. Approximately 1.3% of the shares of the company are short sold. Based on an average trading volume of 2,478,882 shares, the days-to-cover ratio is presently 0.0 days.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Brookline Capital Markets assumed coverage on shares of Ernexa Therapeutics in a report on Thursday, May 7th. They set a “buy” rating and a $30.00 target price for the company. Wall Street Zen raised Ernexa Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $30.00.

Ernexa Therapeutics Price Performance

ERNA stock traded down $0.23 during mid-day trading on Tuesday, reaching $3.69. 7,566 shares of the company’s stock were exchanged, compared to its average volume of 943,616. Ernexa Therapeutics has a 12-month low of $3.18 and a 12-month high of $71.50. The stock’s 50 day moving average is $7.27 and its 200 day moving average is $10.46. The company has a market cap of $4.32 million, a price-to-earnings ratio of -0.14 and a beta of 2.50.

Ernexa Therapeutics (NASDAQ:ERNA) last released its earnings results on Monday, May 11th. The company reported ($6.95) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). On average, research analysts forecast that Ernexa Therapeutics will post -18.02 earnings per share for the current fiscal year.

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.